Dr. Mark Yarchoan is a physician–scientist based in Baltimore who specializes in the treatment and study of gastrointestinal cancers, with a particular focus on liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, where he joined the faculty in 2018. Dr. Yarchoan leads a research laboratory dedicated to developing novel immunotherapies for liver cancers. His translational research program integrates analyses of clinical trial biospecimens with preclinical modeling to identify and overcome barriers to effective antitumor immunity. A major focus of his work is the development of therapeutic cancer vaccines for hepatobiliary malignancies. He serves as Principal Investigator on multiple clinical trials for hepatobiliary cancers, contributes to international guideline committees for liver cancer, and is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology. Dr. Yarchoan’s contributions have been recognized with numerous honors, including the ASCO Young Investigator Award, the Conquer Cancer Foundation Career Development Award, the Mark R. Clements Award from the Cholangiocarcinoma Foundation, and the Blue Faery Award for Excellence in Liver Cancer Research. Dr. Yarchoan is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy.

Marina Baretti, MD, is an assistant professor at Johns Hopkins University School of Medicine and the Jiasheng Chair in Hepato-Biliary Cancer Research. She also serves as Co-Director of the Liver and Biliary Cancer Multidisciplinary Clinic at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). Dr. Baretti received her medical degree from the University of Pisa in Italy. She completed her internal medicine residency and oncology fellowship at University of Milan. She then went on and completed her Postdoctoral and Medical Oncology Fellowship at Johns Hopkins University, Baltimore, Maryland. She is deeply engaged in bridging the gap between laboratory discoveries and clinical application, working closely with laboratory-based scientists to accelerate the development of novel therapeutic strategies. Her academic research is centered on the development of novel agents in hepatobiliary cancers, with particular interest in combinatorial approaches of immunotherapies. She is currently the principal investigator on multiple clinical trials in FLC, HCC and cholangiocarcinoma at Johns Hopkins University, collaborating closely with laboratory-based researchers to move laboratory findings into patients. Through her work, Dr. Baretti strives to improve outcomes for patients with rare GI cancers by identifying innovative therapies that are informed by a deeper understanding of tumor biology and the tumor microenvironment. Dr. Baretti was the recipient of the 2018 American Society of Clinical Oncology Young Investigator Award. Dr. Baretti was also awarded with the 2020 Career Development Award for the MD Anderson Cancer Center’s pancreatic cancer NCI Specialized Programs of Research Excellence (SPORE). Dr. Baretti is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, and Pancreatic Cancer.

Dr. Kelvin K. Hong is an Associate Professor and Executive Vice Chair of Radiology within the Johns Hopkins Department of Radiology. A specialist in interventional and vascular radiology, Dr. Hong serves as the Medical Director of the Johns Hopkins Interventional Radiology Center. Dr. Hong earned his medical degree from South Africa’s University Of Witwatersrand Medical School in Parktown. He completed a radiology residency at Parktown West’s College of Medicine/Radiology, as well as a cardiovascular/interventional radiology fellowship and diagnostic radiology residency at The Johns Hopkins Hospital. His areas of clinical expertise include bone, liver and soft-tissue tumors; chronic total occlusions; claudication; deep venous thrombosis; lung, esophageal and kidney cancer; peripheral arterial/vascular disease; renal artery/vascular disease; uterine fibroid tumors; varicocele; and vascular malformations and venous thromboembolism. Dr. Hong performs procedures that include radiofrequency ablation for lung, liver, kidney and bone lesions; transcatheter arterial chemoembolization for liver cancer; lower-extremity angioplasty and stenting; visceral angioplasty and stenting; embolization of uterine fibroid tumors; cryoablation for pain control; and percutaneous laser ablation of varicose veins. Dr. Hong served as editor for the book Percutaneous Tumor Ablation and contributed to Interventional Oncology: Principles and Practice. Dr. Hong is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Bile Duct Obstruction, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy.

Dr. Georgiades earned a series of degrees (BSc-Mechanical Engineering, MS & PhD-Radiological Sciences and an MD). He received a 1-year training in Internal Medicine at Harvard and subsequently, completed subspecialty training at Johns Hopkins in Diagnostic and Interventional Radiology. He has been a full time faculty at Johns Hopkins since 2003 (except for a 3 year hiatus 2012-2015 when he set up a private practice overseas). He has held various positions including fellowship director, clinical director and was a member of many Departmental and Institutional committees. He is a prolific researcher with more than 100 manuscripts, more than 100 abstracts, 28 book chapters and numerous presentations at national and international fora. Dr. Georgiades is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Bile Duct Obstruction, Neuroendocrine Tumor, Liver Embolization, and Gastrostomy.

Dr. Hamilton is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology. He is the Interim Director, Division of Gastroenterology and Hepatology and the Director of Hepatology for Johns Hopkins Medicine. His clinical specialties include Wilson Disease, Cystic Fibrosis related liver disease, liver transplantation, hepatocellular carcinoma, cirrhosis, portal hypertension, acute and chronic viral, non-alcoholic fatty liver disease (NASH), autoimmune, and cholestatic liver disease. His research interests include the copper homeostasis and its regulation of lipid metabolism and liver injury, the fundamental mechanisms regulating liver fibrosis, and the molecular genetics of hepatocellular carcinoma and early detection biomarkers. Dr. Hamilton is a 2005 recipient of the National Institutes of Health/ National Research Scholar Award for gastroenterology and hepatology. Dr. Hamilton is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Hepatitis, Esophageal Varices, Autoimmune Hepatitis, Endoscopy, and Carotid Artery Surgery.

Dr. Ross C. Donehower is an oncologist in the Baltimore area, caring for patients with gastrointestinal cancers. He was part of the team that developed premedications that allowed paclitaxel — a chemotherapy medication now used to treat several types of cancers — to be safely given to patients. The Virginia and D.K. Ludwig Professor in Clinical Investigation of Cancer, he serves as the director of the Hematology & Medical Oncology Fellowship Program and director of the Division of Medical Oncology at the Johns Hopkins School of Medicine. Dr. Donehower received his undergraduate degree from Hamline University and earned his M.D. from the University of Minnesota. He completed his residency at The Johns Hopkins Hospital. Dr. Donehower joined the Johns Hopkins faculty in 1980. Prior to joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate of the medicine branch and clinical pharmacology branch at the National Cancer Institute. His research interests include gastrointestinal cancers, new anticancer drug development and pharmacology. Dr. Donehower serves on the editorial boards of numerous scholarly journals, including the International Journal of Oncology. He has been recognized by the American Society of Clinical Oncology with a 2017 Excellence in Teaching Award. He is a member of several professional organizations, including the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Donehower is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Natarajan Ravendhran is a hepatologist specializing in the diagnosis, treatment and management of liver diseases. He received his medical degree from Stanley Medical College, University of Madras in India, completed his residency in internal medicine at what is now Ascension Saint Agnes Hospital in Maryland and a residency in surgery at Railway Hospital in Madras, India. Dr. Ravendhran performed fellowship training in hepatology under the mentorship of Eugene and Leon Schiff at the University of Miami. Additionally, he received fellowship training in gastroenterology and liver disease at the University of Missouri. Dr. Ravendhran received a master’s degree in business administration in medical services management from The Johns Hopkins University. He is a fellow of the American Association for the Study of Liver Diseases and the American Gastroenterological Association, and is a member of the European Association for the Study of the Liver. Dr. Ravendhran is interested in exploring cholestatic disorders. He has participated in many clinical trials that focus on hepatitis B and C, in addition to metabolic dysfunction-associated steatotic liver disease trials. He enjoys teaching, rounding with fellows and seeing patients, and his motto is “Patients come first!”. Dr. Ravendhran is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Hepatitis, Visceromegaly, Enlarged Liver, and Endoscopy.

Dr. Po-Hung (Victor) Chen is a transplant hepatology and addiction medicine physician. He is jointly appointed by the Division of Gastroenterology and Hepatology and the Division of Addiction Medicine. Dr. Chen's clinical focus is to care for patients with general or transplant-related liver conditions, including alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, autoimmune liver diseases, hemochromatosis, and other diagnoses. He directed the creation of a Johns Hopkins Medicine informational webpage on ALD. He is also a frequent consultant for other Johns Hopkins clinicians regarding inquiries about ALD, including biomarker interpretation, acute hepatitis management, and addiction treatment delivery. Dr. Chen is a member of multiple professional medical and public health organizations (see below). He is a Fellow of the American College of Gastroenterology and a Fellow of the American Society of Addiction Medicine. Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Hepatitis, Hepatitis C, Alcoholic Cirrhosis, Liver Transplant, and Endoscopy.

Elizabeth Jaffee is an Oncologist in Baltimore, Maryland. Dr. Jaffee is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Fibrolamellar Carcinoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

"Dr. Katarzyna J. Macura is a professor in the Johns Hopkins Medicine department of radiology and radiological science, a professor of oncology and urology at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Precision Medicine Center of Excellence for Prostate Cancer. She is a radiologist consultant for the Prostate Cancer Multidisciplinary Clinic at The Johns Hopkins Hospital in Baltimore, MD. Dr. Macura established a clinical and research prostate imaging program with a focus on magnetic resonance imaging (MRI). Dr. Macura has expertise in cross-sectional body imaging, MRI and prostate cancer, and image-guided biopsies. Dr. Macura earned her medical degree from the Medical University of Lodz in Poland. She completed a residency in diagnostic radiology at the Medical College of Georgia and a fellowship in cross-sectional body imaging at Johns Hopkins University. Prior to arrival at Hopkins in 2000, Dr. Macura completed post-doctoral research in Artificial Intelligence at the University of Georgia in Athens, GA. With a PhD degree in Medical Informatics, she had pioneered early applications of Artificial Intelligence for medical decision support, a domain that is now rapidly expanding owing to the advancement of computer technologies and recent recognition that decision support augments appropriate utilization of medical technologies, provides second opinion systems for improved diagnostics and management, and allows optimization of medical care delivery with the assessment of quality and safety. Dr. Macura is a certified knowledge engineer. Dr. Macura is a member of several national and international radiology organizations. She served as president of the Maryland Radiological Society, the Maryland Chapter of the American College of Radiology (ACR), between 2013 and 2015, as well as president of the American Association for Women in Radiology (AAWR) in 2005. She was a Chancellor on the ACR Board of Chancellors, serving as the Inaugural Chair of the ACR Commission for Women and Diversity, between 2013 and 2019. She served as Vice-President of the ACR 2019-2020. She was named the Outstanding Teacher of the Year by Hopkins Radiology Residents in 2005 and 2021, and received the Resident Mentoring Awards in 2018 and 2024. Dr. Macura was also named the Honored Educator by the Radiological Society of North America in 2012 and 2014. In 2016, she received the ""Diamond"" Jim Brady Urology Residents teaching award and the AAWR Marie Sklodowska-Curie award. In 2022, she received the Gold Medal from the American College of Radiology. Dr. Macura is a Fellow of the American College of Radiology (FACR), the Society for Advanced Body Imaging (FSABI), and the American Association for Women in Radiology (FAAWR).". Dr. Macura is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Muscle Invasive Bladder Cancer, Fibrolamellar Carcinoma, Renal Cell Carcinoma (RCC), Prostatectomy, and Penectomy.

Dr. Linda Chi Hang Chu is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Her clinical expertise includes body CT, MRI and US. Her research interests include abdominal imaging, cancer imaging, radiomics, and artificial intelligence. Dr. Chu graduated from the University of Toronto in 2003 and was awarded the Governor General's Silver Medal, the highest academic achievement from the undergraduate program. She earned her medical degree as a member of AOA and phi beta kappa from Johns Hopkins University in Baltimore, MD in 2007. She completed her Diagnostic Radiology residency and body MRI fellowship at Johns Hopkins Hospital. Dr. Chu joined the Johns Hopkins faculty in 2013. Dr. Chu is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, Muscle Invasive Bladder Cancer, Pancreaticoduodenectomy, and Gallbladder Removal.

Dr. Stefan Loy Zimmerman is a Professor in the Johns Hopkins University School of Medicine in the Departments of Radiology and Medicine (Cardiology). He specializes in cardiothoracic imaging and is the Division Director of Diagnostic Imaging and Director of Cardiac Imaging. He is the program director for the Cardiothoracic Imaging Fellowship in Radiology. Dr. Zimmerman earned his medical degree from the University of Pennsylvania School of Medicine. He completed both a radiology residency and a cardiovascular imaging fellowship at the Hospital of the University of Pennsylvania. His research focuses on the use of CT and MR imaging in the diagnosis and management of cardiovascular diseases. He has particular interest in the use of cardiac imaging for management of arrhythmias, diagnosis and prognosis of arrhythmogenic right and left ventricular cardiomyopathy, and pulmonary hypertension. Dr. Zimmerman is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Paroxysmal Supraventricular Tachycardia (PSVT), Alveolar Soft Part Sarcoma, Liposarcoma, Cardiac Ablation, and Transcatheter Aortic Valve Replacement (TAVR).

Debashish Bose is a Surgical Oncologist and a General Surgeon in Baltimore, Maryland. Dr. Bose is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Pancreatic Pseudocyst, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bose is currently accepting new patients.

Dr. Robert Liddell is an Assistant Professor of Radiology and Surgery and Division Chief of Interventional Radiology at the Johns Hopkins School of Medicine. His specialty is interventional radiology, with an expertise in interventional oncology and vascular and interventional radiology. Dr. Liddell received his MBBCh at the Royal College of Surgeons in Ireland. He completed his residency at Johns Hopkins University School of Medicine in Diagnostic Radiology and his fellowship in Interventional Radiology. Videos Interventional Radiology. Dr. Liddell is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Bile Duct Obstruction, Ascites, Fibrolamellar Carcinoma, Liver Embolization, and Pancreaticoduodenectomy.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Gurakar joined Johns Hopkins from the Nazih Zuhdi Transplantation Institute at the Integris Baptist Medical Center in Oklahoma City, where he was the chief of Hepatology Research and the program director of the Liver Transplantation Medicine/ Hepatology Fellowship. He served at various capacities in the Liver Medicine Section, since its first establishment in 1993. Dr. Gurakar's clinical interests include pre and post-transplant, clinical and endoscopic management of liver diseases and viral hepatitis. His research interests include bioartificial liver dialysis systems and application of total plasma exchange in the treatment of liver disorders. Dr. Gurakar is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Hepatitis, Liver Failure, Alcoholic Cirrhosis, Liver Transplant, and Kidney Transplant.

Kelly Lafaro, MD, MPH, is a general surgeon with a specialty in gastrointestinal surgical oncology and hepatobiliary surgery. She is part of the Johns Hopkins Kimmel Cancer Center. Dr. Lafaro earned her medical degree from Tulane University School of Medicine and completed her residency at New York-Presbyterian/Columbia University Irving Medical Center. Her fellowship in complex general surgical oncology was completed at City of Hope National Medical Center. Dr. Lafaro’s expertise includes pancreatic adenocarcinoma, neuroendocrine tumors, minimally invasive pancreatic and liver surgeries, and colorectal liver metastases. In addition to her clinical experience, Dr. Lafaro is published in the field of liver and pancreatic cancer. She is interested in the improvement of surgical and post-surgical outcomes. Dr. Lafaro is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreatectomy, and Pancreaticoduodenectomy.

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.

Dr. Won Jin Ho is a physician-scientist at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins who focuses on cancer immunology and tumor microenvironment research. Dr. Ho received his BS and MS in Biomedical Engineering from University of California, Los Angeles, and his MD from Wayne State University School of Medicine. Dr. Ho completed a research track internal medicine residency as an NIH F32 postdoctoral fellow at Case Western Reserve University and subsequently completed a medical oncology fellowship at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as the recipient of ASCO Young Investigator Award and AACR Immuno-Oncology Fellowship. Dr. Ho's overarching research interest is to develop novel immunotherapeutic strategies even against immune-resistant cancers by first understanding the immune responses to current therapeutics. Dr. Ho focuses on determining the systemic and in situ changes by leveraging cutting-edge technologies. With his expertise in mass cytometry, Dr. Ho is co-leading many of the systemic and spatial immune profiling efforts at Johns Hopkins. Dr. Ho also is developing novel small-molecule cancer therapeutics and methodologies for translational discovery. Dr. Ho is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Fibrolamellar Carcinoma, Liver Cancer, and Hepato-Pancreato-Biliary Surgery.